Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97
November 12, 2015 9:29 AM ESTPiper Jaffray reiterates an Overweight rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $97.00 (from $120.00), following the company's 3Q earnings report. Eagle reported EPS of ($0.65) on revenues of $6M, missing consensus on both. Analyst David Amsellem continues to believe there is optionality associated with Ryanodex in exertional heat stroke (EHS),... More
